EPISODE · Apr 25, 2022 · 29 MIN
A vision for the future: Can Britain become a biotech superpower?
The UK's vaccine programme was hailed by the government as a success story for Global Britain. It became an example of how Britain could speed up regulation, reduce bureaucracy and become a worldwide home for tech and innovation in life sciences. The government recently published a Life Sciences Vision, but how much vision was there? This podcast will look at the importance of the industry, the hurdles that it faces and its contribution to the government's Global Britain agenda. Fraser Nelson, the editor of The Spectator is joined by Anthony Browne, Conservative MP for South Cambridgeshire; Zoe Martin, a policy manager at Cancer Research and Samin Saeed who is the medical director & chief scientific officer for Novartis Pharmaceuticals UK Ltd. This podcast is kindly sponsored by Novartis Pharmaceuticals UK Ltd. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
The UK's vaccine programme was hailed by the government as a success story for Global Britain. It became an example of how Britain could speed up regulation, reduce bureaucracy and become a worldwide home for tech and innovation in life sciences. The government recently published a Life Sciences Vision, but how much vision was there? This podcast will look at the importance of the industry, the hurdles that it faces and its contribution to the government's Global Britain agenda. Fraser Nelson, the editor of The Spectator is joined by Anthony Browne, Conservative MP for South Cambridgeshire; Zoe Martin, a policy manager at Cancer Research and Samin Saeed who is the medical director & chief scientific officer for Novartis Pharmaceuticals UK Ltd. This podcast is kindly sponsored by Novartis Pharmaceuticals UK Ltd. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
A vision for the future: Can Britain become a biotech superpower?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m